ARK Investment Management LLC Buys 471,897 Shares of Compass Pathways PLC Sponsored ADR $CMPS

ARK Investment Management LLC raised its stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 28.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,121,118 shares of the company’s stock after purchasing an additional 471,897 shares during the quarter. ARK Investment Management LLC owned 2.21% of Compass Pathways worth $12,154,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Simplify Asset Management Inc. bought a new stake in shares of Compass Pathways during the 3rd quarter worth $1,662,000. Eagle Health Investments LP bought a new stake in Compass Pathways during the third quarter worth about $5,360,000. Bridger Management LLC purchased a new position in shares of Compass Pathways in the 2nd quarter worth about $412,000. Schroder Investment Management Group bought a new position in shares of Compass Pathways during the 2nd quarter valued at about $1,525,000. Finally, Hsbc Holdings PLC bought a new position in shares of Compass Pathways during the 2nd quarter valued at about $3,011,000. Institutional investors own 46.19% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on CMPS. Canaccord Genuity Group boosted their target price on Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Royal Bank Of Canada upped their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Compass Point set a $15.00 price objective on Compass Pathways in a research note on Thursday, February 12th. Finally, HC Wainwright boosted their target price on Compass Pathways from $40.00 to $70.00 and gave the company a “buy” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.13.

Compass Pathways Price Performance

Shares of NASDAQ CMPS opened at $7.05 on Thursday. Compass Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $8.90. The stock has a market capitalization of $676.94 million, a P/E ratio of -2.59 and a beta of 1.90. The company’s 50-day moving average is $6.99 and its 200 day moving average is $6.12. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.